Relmada, which has turned to strategic options after scrapping two phase 3 trials in major depressive disorder (MDD), is ...
Relmada Therapeutics has announced the acquisition of Sepranolone, a Phase 2b ready neurosteroid developed for treating Tourette syndrome (TS) and related compulsive disorders, from Asarina Pharma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results